Dr. Weise is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2800 W. Grand Blvd
Detroit, MI 48202Phone+1 313-492-0906
Education & Training
Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 2004 - 2007
Eastern Virginia Medical SchoolResidency, Internal Medicine, 2001 - 2004
Michigan State University College of Osteopathic MedicineClass of 1996
Certifications & Licensure
MI State License 2004 - 2026
VA State License 1997 - 2008- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors Start of enrollment: 2021 Mar 19
Roles: Contact
Publications & Presentations
PubMed
- 3 citationsPhase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.Omid Hamid, Karl D Lewis, Amy Weise, Meredith McKean, Kyriakos P Papadopoulos
Journal of Clinical Oncology. 2024-08-20 - 26 citationsA First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.Mrinal M Gounder, Todd M Bauer, Gary K Schwartz, Amy M Weise, Patricia LoRusso
Journal of Clinical Oncology. 2023-03-20 - 12 citationsFirst-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.Khanh T. Do, Laura Q.M. Chow, Karen L. Reckamp, Rachel E. Sanborn, Howard A. Burris
The Oncologist. 2021-11-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
